BGT Stock Overview
An agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bio-Gene Technology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.049 |
| 52 Week High | AU$0.085 |
| 52 Week Low | AU$0.028 |
| Beta | 0.65 |
| 1 Month Change | 13.95% |
| 3 Month Change | -10.91% |
| 1 Year Change | -12.50% |
| 3 Year Change | -77.73% |
| 5 Year Change | -71.18% |
| Change since IPO | -75.50% |
Recent News & Updates
Recent updates
We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely
Feb 22
Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Oct 25Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation
Jun 20Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future
Apr 28What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation
Jan 11Shareholder Returns
| BGT | AU Chemicals | AU Market | |
|---|---|---|---|
| 7D | 75.0% | 1.5% | 1.4% |
| 1Y | -12.5% | 0.2% | 9.2% |
Return vs Industry: BGT underperformed the Australian Chemicals industry which returned 0.2% over the past year.
Return vs Market: BGT underperformed the Australian Market which returned 9.2% over the past year.
Price Volatility
| BGT volatility | |
|---|---|
| BGT Average Weekly Movement | 29.5% |
| Chemicals Industry Average Movement | 10.3% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.3% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: BGT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BGT's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | Tim Grogan | www.bio-gene.com.au |
Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University to support research and field operations relating to processing and distillation of oil from biomass; AgriFor Scientific, a chemistry product; cesar for assessing the insecticidal activity of molecules against a various insect species; CSIRO, a chemistry development process; Department of Agriculture and Fisheries, Queensland Government for assessing activity against grain storage pests; Eurofins; Grain Research Development Corporation; Pacific Discovery Services; Purdue University; Southern Cross University, a chemical analysis of natural products; University of Florida; and University of Technology.
Bio-Gene Technology Limited Fundamentals Summary
| BGT fundamental statistics | |
|---|---|
| Market cap | AU$9.87m |
| Earnings (TTM) | -AU$2.41m |
| Revenue (TTM) | AU$18.32k |
538.6x
P/S Ratio-4.1x
P/E RatioIs BGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGT income statement (TTM) | |
|---|---|
| Revenue | AU$18.32k |
| Cost of Revenue | AU$319.77k |
| Gross Profit | -AU$301.45k |
| Other Expenses | AU$2.11m |
| Earnings | -AU$2.41m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | -1,645.46% |
| Net Profit Margin | -13,150.54% |
| Debt/Equity Ratio | 0% |
How did BGT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 08:23 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Gene Technology Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tom Waite | PAC Partners Securities Pty. Ltd. |